These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 17105953)

  • 1. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics.
    Abanades S; Farré M; Segura M; Pichini S; Barral D; Pacifici R; Pellegrini M; Fonseca F; Langohr K; De La Torre R
    Ann N Y Acad Sci; 2006 Aug; 1074():559-76. PubMed ID: 17105953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users.
    Abanades S; Farré M; Barral D; Torrens M; Closas N; Langohr K; Pastor A; de la Torre R
    J Clin Psychopharmacol; 2007 Dec; 27(6):625-38. PubMed ID: 18004131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of gamma-hydroxybutyric acid in conventional and nonconventional biologic fluids after single drug administration: issues in methodology and drug monitoring.
    Abanades S; Farré M; Segura M; Pichini S; Pastor A; Pacifici R; Pellegrini M; de la Torre R
    Ther Drug Monit; 2007 Feb; 29(1):64-70. PubMed ID: 17304152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers.
    Thai D; Dyer JE; Jacob P; Haller CA
    Clin Pharmacol Ther; 2007 Feb; 81(2):178-84. PubMed ID: 17192771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulating properties of gamma-hydroxybutyrate (GHB), flunitrazepam and ethanol in 'club drugs' users.
    Pichini S; Farré M; Abanades S; Pacifici R; Zuccaro P; Langohr K; de la Torre R
    Addict Biol; 2010 Jul; 15(3):336-45. PubMed ID: 20456291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
    Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
    J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of γ-hydroxybutyrate in healthy subjects.
    Liechti ME; Quednow BB; Liakoni E; Dornbierer D; von Rotz R; Gachet MS; Gertsch J; Seifritz E; Bosch OG
    Br J Clin Pharmacol; 2016 May; 81(5):980-8. PubMed ID: 26659543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
    Johnson MW; Suess PE; Griffiths RR
    Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB.
    Carter LP; Richards BD; Mintzer MZ; Griffiths RR
    Neuropsychopharmacology; 2006 Nov; 31(11):2537-51. PubMed ID: 16880774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry.
    van Nieuwenhuijzen PS; McGregor IS
    Drug Alcohol Depend; 2009 Aug; 103(3):137-47. PubMed ID: 19446408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
    Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
    Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB).
    Sumnall HR; Woolfall K; Edwards S; Cole JC; Beynon CM
    Drug Alcohol Depend; 2008 Jan; 92(1-3):286-90. PubMed ID: 17766059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users.
    Zacny JP; Gutierrez S; Bolbolan SA
    Drug Alcohol Depend; 2005 Jun; 78(3):243-52. PubMed ID: 15893155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gamma-hydroxybutyrate detoxification by titration and tapering.
    de Jong CA; Kamal R; Dijkstra BA; de Haan HA
    Eur Addict Res; 2012; 18(1):40-5. PubMed ID: 22142784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence.
    Galloway GP; Frederick SL; Staggers FE; Gonzales M; Stalcup SA; Smith DE
    Addiction; 1997 Jan; 92(1):89-96. PubMed ID: 9060200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
    Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
    Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gamma-hydroxybutyrate--an endogenous substance and a new central nervous system stimulant. Clinical aspects of acute poisoning].
    Engelsen J; Christensen HR
    Ugeskr Laeger; 1999 Dec; 161(50):6903-7. PubMed ID: 10643375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of gamma-hydroxybutyrate in striatal microdialysates following peripheral 1,4-butanediol administration in rats.
    Kapadia R; Böhlke M; Maher TJ
    Life Sci; 2007 Feb; 80(11):1046-50. PubMed ID: 17188717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gamma-hydroxybutyrate--a drug of abuse.
    Drasbek KR; Christensen J; Jensen K
    Acta Neurol Scand; 2006 Sep; 114(3):145-56. PubMed ID: 16911342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.
    Busardò FP; Jones AW
    Curr Neuropharmacol; 2015 Jan; 13(1):47-70. PubMed ID: 26074743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.